IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2129-2132

  Shalhoub, Sarah ^a   Farahat, Fayssal ^b   Al Jiffri, Abdullah ^a   Simhairi, Raed ^a   Shamma, Omar ^a   Siddiqi, Nauman ^a   Mushtaq, Adnan ^a  

^a KING FAHD ARMED FORCES HOSPITAL   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Interferon; MERS CoV; Treatment

Indexed keywords

ALPHA2A INTERFERON; BETA1A INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FEVER; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS PNEUMONIA; MORTALITY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; VIRUS PNEUMONIA; VIRUS SHEDDING;

EID: 84936931504     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv085     Document Type: Article

References (16)

1. Al-Tawfiq JA, Hinedi K, Ghandour J et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014; 59: 160-5.
2. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13: 752-61.
3. Yang Y, Zhang L, Geng H et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013; 4: 951-61.
4. Niemeyer D, Zillinger T, Muth D et al. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 2013; 87: 12489-95.
5. Faure E, Poissy J, Goffard A et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 2014; 9: e88716.
6. de Wilde AH, Raj VS, Oudshoorn D et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment. J Gen Virol 2013; 94: 1749-60.
7. Falzarano D, de Wit E, Martellaro C et al. Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin. Sci Rep 2013; 3: 1686.
8. Falzarano D, de Wit E, Rasmussen AL et al. Treatment with interferona2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19: 1313-7.
9. Al-Tawfiq JA, Momattin H, Dib J et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20: 42-6.
10. Omrani AS, Saad MM, Baig K et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14: 1090-5.
11. Hart BJ, Dyall J, Postnikova E et al. Interferon-b andmycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95: 571-7.
12. WHO. Revised Case Definition for Reporting to WHO-Middle East Respiratory Syndrome Coronavirus. Interim Case Definition as of 14 July 2013. http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/.
13. CDC. Middle East Respiratory Syndrome (MERS), Case Definitions. http://www.cdc.gov/coronavirus/mers/case-def.html.
14. Corman VM, Eckerle I, Bleicker T et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012; 17: pii=20285.
15. Mair-Jenkins J, Saavedra-Campos M, Baillie K et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80-90.
16. Memish ZA, Al-Tawfiq JA, Makhdoom HQ et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 2014; 210: 1590-4.